First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 11; 18(11):1483-1492.

View in: PubMed

subject areas

Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Carcinoma, Transitional Cell
Cisplatin
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Humans
Infusions, Intravenous
Internationality
Maximum Tolerated Dose
Middle Aged
Neoplasm Invasiveness
Neoplasm Staging
Patient Safety
Prognosis
Prospective Studies
Single-Blind Method
Survival Analysis
Treatment Outcome
Urologic Neoplasms

authors with profiles

Peter H. O'Donnell